Yale professor Craig Crews says the partnershop reflects "a new paradigm" of how academics and the pharmaceutical industry can partner.

UK-based pharmaceutical company GlaxoSmithKline and US-based Yale University [the Beinecke Library is pictured] set up a drug discovery research collaboration on Tuesday last week.

The partnership is designed to develop Yale’s work on "proteolysis targeting chimeric molecules", which help the body destroy disease-causing proteins. The two institutions are looking to show these molecules can be turned into medicines.

The pair said in a statement: "GSK will then have the right to use this technology for multiple disease-causing proteins across all therapy areas.  For each protein-degrading drug that is discovered and developed, Yale will be eligible for milestone and royalty payments."

Kris Famm, head of GSK’s Protein Degradation effort will lead the programme with Craig Crews, the Lewis B. Cullman Professor of Molecular, Cellular, and Developmental Biology at Yale. 

Crews said:  "The relationship between the pharmaceutical industry and academia is changing and this collaboration offers a new paradigm for how pharma…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?